Lucas Moreno Martín-Retortillo

I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels

Instituciones de las que forman parte

Jefe de grupo
Cáncer y Enfermedades Hematológicas Infantiles

Vall Hebron Institut de Recerca

Director clínico
Oncología y Hematología Pediátrica

Hospital Infantil i Hospital de la Mujer

Lucas Moreno Martín-Retortillo

Instituciones de las que forman parte

Jefe de grupo
Cáncer y Enfermedades Hematológicas Infantiles

Vall Hebron Institut de Recerca

Director clínico
Oncología y Hematología Pediátrica

Hospital Infantil i Hospital de la Mujer

Dr. Lucas Moreno just moved to Barcelona to lead the Paediatric Oncology & Haematology Division at Vall d'Hebron Hospital. He has devoted his career to childhood cancer drug development. His main research interest is in neuroblastoma, one of the most aggressive forms of childhood cancer.
After returning from London where he worked at the Royal Marsden Hospital from 2008 to 2012, he created and led the Clinical Trials Unit at Hospital Niño Jesús (Madrid) that became a leading trials unit for paediatric drug development nationally and internationally.
He is a key opinion leader in neuroblastoma and drug development in Europe and works for international networks such as SIOPEN (siopen.net) and ITCC (itcc-consortium.org). He leads the BEACON-Neuroblastoma trial open in 10 European countries for relapsed & refractory neuroblastoma. He has been principal investigator of more than 30 clinical trials and has co-authored more than 60 international publications in the field.
He provides second opinion consultations for children and adolescents with relapsed/refractory cancers nationally and internationally to facilitate access to early clinical trials and novel agents.
He is a keen supporter of incorporating the patient/parents voice into research and clinical practice and has started several projects on quality of life, quality of care, late effects and patient reported outcomes. His favourite conference of the year is the Solving Kids’ Cancer Parent conference because of the excellent interaction between researchers, clinicians and parents.

Proyectos

Next generation personalised medicine for childhood cancers

IP: Lucas Moreno Martín-Retortillo
Colaboradores: Aroa Soriano Fernández, Jessica Camacho Soriano, Raquel Hladun Alvaro, Gabriela Guillén Burrieza, Andrea Vilaplana Blanes, Paula Cabre Fernandez, Lorena Valero Arrese, Sergio Manresa Vera, Mariona Morell Daniel
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 214170
Referencia: PI21/01661
Duración: 01/01/2022 - 31/12/2024

BEACON-BIO: deep biological characterisation and development of biomarkers for relapsed neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Colaboradores: Andrea Vilaplana Blanes, María Rosario Pérez- Torres Lobato
Entidad financiadora: European Science Foundation
Financiación: 104500
Referencia: BEACON-BIO_FKC_2021
Duración: 01/01/2022 - 31/12/2023

International integrated analysis to identify markers of poor survival in high-risk neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Colaboradores: Andrea Vilaplana Blanes, Mariona Morell Daniel
Entidad financiadora: Solving Kids’ Cancer
Financiación: 131766.91
Referencia: SKC/AEFRM/2020/MORENO
Duración: 02/11/2020 - 01/11/2023

Quatsomes as a novel nanomaterial platform for nucleic acids delivery

IP: Miguel Segura Ginard
Colaboradores: Soledad Gallego Melcón, Aroa Soriano Fernández, Ariadna Boloix Amenós, Lucas Moreno Martín-Retortillo
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 83600
Referencia: DTS20/00018
Duración: 01/01/2021 - 31/12/2022